Val Guild Honored at 2022 ASCO Annual Conference
by Alicia Rowell, Vice President Saturday, June 4 was a special evening. In Chicago that week many of the nation’s…
Blog - Melanoma360
09/29/2022
Val Guild Honored at 2022 ASCO Annual Conference
by Alicia Rowell, Vice President Saturday, June 4 was a special evening. In Chicago that week many of the nation’s…
|
09/27/2022
President’s Letter | September 2022
From the Desk of Samantha Guild Leaves are falling, pumpkins are out, football is on TV, and the kids are…
|
09/27/2022
AIM Welcomes Ann Garst Taylor as New Director of Community Engagement
By Mara Klecker Ann Garst Taylor, AIM at Melanoma’s new Director of Community Engagement, has nearly 30 years of volunteer…
|
09/16/2022
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
(NEWS PROVIDED BY Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
|
09/13/2022
Spirituality and Cancer Care With Michael Eselun, BCC
When faced with a cancer diagnosis, some patients rely on their spirituality to cope and find meaning behind the experience.…
|
09/13/2022
ESMO: TIL therapy improves on Yervoy in melanoma trial
(NEWS PROVIDED BY Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
|
09/12/2022
Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
|
09/11/2022
Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma
Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
|
09/06/2022
Survivor Spotlight: Erich & Jenn Djordjevic
By Mara Klecker Note: Erich passed away on September 28th, 2022, the same week his story ran in our newsletter.…
|
09/06/2022
Survivor Spotlight: Bev Johnson, Mucosal Melanoma Survivor
By Mara Klecker Bev Johnson figured the abnormal bleeding she was experiencing was a side effect of her IUD losing…
|
Recent Posts
May. 01, 2025
AIM at Melanoma + WEARSPF®: Partnering for a Cause This Melanoma Awareness Month
May. 01, 2025
Hope, Purpose, and Progress: Melanoma Awareness Month with AIM
Apr. 28, 2025
Your Style Can Save Lives – Lilly Pulitzer Giving Day is Here!
Apr. 28, 2025
From Diagnosis to Crown: Miss Pennsylvania’s Journey of Advocacy and Awareness
Apr. 24, 2025